Merck & Co., Inc. (6MK.DE)
| Previous close | 120.60 |
| Open | 121.00 |
| Bid | 122.80 x 0 |
| Ask | 122.80 x 0 |
| Day's range | 121.00 - 123.00 |
| 52-week range | 91.00 - 124.40 |
| Volume | |
| Avg. volume | 996 |
| Market cap | 315.641B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 146.43 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.36%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Benzinga
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
- Zacks
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
- Insider Monkey
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
